Form 4: ANI Pharmaceuticals Director Antonio Pera Granted Restricted Stock Award

Antonio R. Pera, a Director at ANI Pharmaceuticals, Inc., has been granted 4,336 shares of common stock as a restricted stock award, set to vest in May 2026.

Summary

• Antonio R. Pera, a Director of ANI Pharmaceuticals, Inc. (ANIP), acquired 4,336 shares of common stock on May 22, 2025.
• The acquisition was a restricted stock award, meaning the shares were granted at a price of $0.
• These shares will vest in full on May 22, 2026.
• Following this transaction, Mr. Pera beneficially owns a total of 35,373 shares of ANI Pharmaceuticals common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard practice of aligning director incentives with shareholder value, without indicating any negative operational or financial news for the company.

Positives

• The restricted stock award aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• It represents a standard form of equity compensation for corporate directors.

Negatives

• No direct negatives are indicated by this specific transaction, as it is a routine compensation grant.

Risks

• The value of the restricted stock award is subject to the future market price fluctuations of ANI Pharmaceuticals' common stock.

Future Outlook

The document indicates that the restricted stock award will vest in full on May 22, 2026, which is a future event impacting the director's beneficial ownership.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across publicly traded companies as part of their executive and director compensation programs. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The grant of a restricted stock award to Antonio R. Pera, a Director of ANI Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The award aims to align the director's long-term interests with shareholder value creation.
• Director (Antonio R. Pera): Receives equity compensation, increasing his beneficial ownership in the company.

Next Steps

• The restricted stock award of 4,336 shares will vest in full on May 22, 2026.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Form 4, Restricted Stock Award, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership